Mirum Pharma rises after liver disease drug meets main goal in trial

Mirum Pharmaceuticals

04/05/2026 15:53

** Shares of biotech firm Mirum Pharmaceuticals MIRM.O rise 11.9% to $108.09

** Co says its experimental drug,volixibat, met the main goal of a mid-stage study by reducing severe itching in patients with primary sclerosing cholangitis, a type of rare liver disease

** Says the drug cut itch scores by 2.72 points from baseline, versus 1.08 points for placebo, giving a placebo-adjusted benefit of 1.64 points

** "We expect shares to be up modestly as success in PSC may have been expected given the bogey was low considering there are no approved drugs," RBC Capital Markets says

** Including session's move, MIRM up 36.1% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))